• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 24, 2015

View Archived Issues

Amgen and Allergan have Avastin in their sights with phase III biosimilar findings

Partners Amgen Inc. and Allergan plc said the phase III study of ABP 215 – a biosimilars candidate to Avastin (bevacizumab, Genentech Inc./Roche AG) and the first in the oncology collaboration to complete a late-stage trial – met its primary and secondary endpoints in comparing efficacy and safety to the reference drug in adults with advanced non-squamous non-small-cell lung cancer (NSCLC). Read More

Execs are in DoJ's crosshairs as FDA revisits off-label issue

As the off-label promotion issue continues to populate court dockets, the FDA is working on a document that will address the problem. Read More

Adoption picks up speed after Remicade biosimilar hit European markets

LONDON – After a slow start following the first approval in 2006, adoption of biosimilars in Europe is now picking up pace in the face of pressure from payers, increased understanding by physicians and the availability of more products addressing underserved patient populations. Read More

From 'Heron' out, pain combo phase II winner aiming at bupivacaine

What one analyst described as Heron Therapeutics Inc.'s "profound benefit" in phase II data with HTX-011 for post-bunionectomy pain triggered speculation about how the findings might translate into a pivotal trial with the compound, a long-acting formulation of the numbing agent bupivacaine in a fixed-dose pairing with the anti-inflammatory therapy meloxicam. Read More

Oncogenex: Pancreatic miss doesn't dim hopes for apatorsen program

With multiple midstage trials ongoing of apatorsen in several cancer types, Oncogenex Pharmaceuticals Inc. is unlikely to spend too much time ruminating on the failure of the phase II Ranier trial testing the drug, formerly known as OGX-427, in pancreatic cancer, an arguably long-shot indication from the start. Read More

Financings

Regenxbio Inc., of Rockville, Md., closed its IPO of 7.245 million shares of common stock at $22 per share, which included 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. Read More

Other news to note

Hemispherx Biopharma Inc., of Philadelphia, said authors of a peer-reviewed article published in Clinical and Cellular Immunology observed that Ampligen, a Toll-like receptor 3 (TLR3) agonist, unlike all other Toll-like receptors studied to date, has a mechanism of action making it potentially adaptable as a treatment for disorders such as multiple sclerosis (MS). Read More

Stock movers

Read More

In the clinic

Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., completed development of the protocol for a phase Ib/II trial of its investigational cancer therapy PV-10 in combination with the anti-PD-1 immune checkpoint inhibitor Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with stage IV melanoma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Kymera’s phase I data lead big week for STAT6 space

    BioWorld
    It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe